Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Barinthus Biotherapeutics plc.BRNS · Entity 9597 | Chief Financial Officer | February 03, 2025 | February 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Barinthus Biotherapeutics plc.
Report date February 03, 2025 · Filed February 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-02-03 | Direct | 160,000 |
Reported balance
After 2025-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-03 · Grant · Acquired 160,000 · Balance 160,000 F1: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026.
F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2025 Filed Feb 5, 2025 21:24 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001828185-25-000012 · wk-form4_1738790675.xml · derivative · entry 1 Brown Gemma · CIK 0001947293 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Ordinary Shares · 160,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on February 3, 2026. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 13:52 UTC | Barinthus Biotherapeutics plc. BRNS · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 193,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001104659-24-001164 · tm241766-1_4seq1.xml · derivative · entry 1 Brown Gemma · CIK 0001947293 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,000 Underlying: Ordinary Shares · 193,000 shares Expires 2034-01-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 2, 2025. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| January 03, 2023 Filed Feb 23, 2023 21:52 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 33,100 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001104659-23-024799 · tm237643-1_4seq1.xml · derivative · entry 1 Brown Gemma · CIK 0001947293 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,100 Underlying: Ordinary Shares · 33,100 shares Expires 2033-01-03 F2 · derivative.exercise_date: This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on January 3, 2024. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:05 UTC | Barinthus Biotherapeutics plc. VACC · Entity 9597 | GrantShare Option (Right to Buy) · Derivative | 334,000 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001104659-22-103706 · tm2226822-1_4seq1.xml · derivative · entry 1 Brown Gemma · CIK 0001947293 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,000 Underlying: Ordinary Shares · 334,000 shares Expires 2032-09-26 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in three equal annual installments, with the first installment vesting on September 15, 2023. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.